4basebio (LON:4BB) Shares Up 0.1% – Time to Buy?

4basebio PLC (LON:4BB)’s stock price was up 0.1% during mid-day trading on Monday . The stock traded as high as GBX 1,170 ($15.06) and last traded at GBX 1,093 ($14.07). Approximately 680 shares were traded during trading, a decline of 6% from the average daily volume of 727 shares. The stock had previously closed at GBX 1,092 ($14.06).

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reiterated an “outperform” rating and issued a GBX 1,600 ($20.60) target price on shares of 4basebio in a research note on Thursday, March 13th.

4basebio Price Performance

The company has a market cap of £144.88 million, a price-to-earnings ratio of -1,450.00 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The company has a fifty day moving average price of GBX 1,149.40 and a two-hundred day moving average price of GBX 1,244.88.

Insider Buying and Selling

In other 4basebio news, insider Amy Walker purchased 1,151 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average price of GBX 1,120 ($14.42) per share, with a total value of £12,891.20 ($16,597.40). 68.44% of the stock is owned by company insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.